A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function

Oncopeptides AB10 个研究点分布在 3 个国家目标入组 35 人开始时间: 2018年8月28日最近更新: 2023年3月10日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方: Oncopeptides AB
入组人数: 35
试验地点: 10
主要终点: Tmax of Melphalan

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.

详细描述

This was a multicenter study assessing the safety, tolerability, and efficacy of melflufen given on Day 1 of a 28-day cycle, together with weekly dexamethasone, in patients with relapsed multiple myeloma or RRMM and impaired renal function, as well as the relationship between renal function and PK parameters for the active metabolite melphalan.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female, age 18 years or older, at the time of signing the informed consent;
•A prior diagnosis of multiple myeloma (MM) with documented disease progression in need of treatment at time of screening;
•Received at least 2 prior lines of therapy;
•Measurable disease defined as any of the following:
•Serum monoclonal protein ≥0.5 g/dL by serum protein electrophoresis (SPEP).
•≥200 mg/24 hours of monoclonal protein in the urine on 24-hour urine electrophoresis (UPEP)
•Serum free light chain (SFLC) ≥10 mg/dL AND abnormal serum kappa to lambda free light chain ratio
•Life expectancy of ≥6 months;
•Eastern Cooperative Oncology Group (ECOG) performance status ≤
•(Patients with lower performance status based solely on bone pain secondary to MM may be eligible following consultation and approval of the medical monitor);
•Patient is a female of childbearing potential (FCBP)* with a negative serum or urine pregnancy test prior to initiation of therapy and agrees to practice appropriate methods of birth control, or the patient is male and agrees to practice appropriate methods of birth control;
•Ability to understand the purpose and risks of the study and provide signed and dated informed consent;
•12-lead electrocardiogram (ECG) with QT interval calculated by Fridericia Formula (QTcF) interval of ≤470 msec;
•Renal function: Estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula on 2 consecutive screening evaluations. Patients meeting criteria for Screening 1, must also meet criteria for Screening 2 following optimal hydration (as determined by the investigator). Screening 2 must be on or as close as possible to treatment start date (preferably <24-48 hours) but cannot exceed 72 hours.
•Cohort 1 (a and b): Screening 1: eGFR between ≥25 mL/min/1.73m² to <45 mL/min/1.73m². Screening 2: eGFR between ≥30 mL/min/1.73m² to <45 mL/min/1.73m².
•Cohort 2 (a and b): Screening 1: eGFR between ≥10 mL/min/1.73m² to <35 mL/min/1.73m². Screening 2: eGFR between ≥15 mL/min/1.73m² to <30 mL/min/1.73m².
•Cohort 2b will only be enrolled following approval of Data Safety Monitoring Committee (DSMC) after evaluating data from Cohort 1a, 1b and 2a.
•Patients with fluctuating values of eGFR may be eligible following consideration of additional assessments in consultation with the medical monitor.
•The following laboratory results must be met during screening (within 21 days) and immediately before study drug administration on Cycle 1 Day 1:
•Absolute neutrophil count (ANC) ≥1,000 cells/mm³ (1.0 x 10⁹/L) (Growth factors cannot be used within 10 days [14 days for pegfilgrastim] prior to initiation of therapy)
•Platelet count ≥75,000 cells/mm³ (75 x 10⁹/L) (without required transfusions during the 10 days prior to initiation of therapy)
•Hemoglobin ≥8.0 g/dL (red blood cell [RBC] transfusions are permitted)
•Total Bilirubin ≤1.5 x upper limit of normal (ULN), or higher in patients diagnosed with Gilbert's syndrome, that have been reviewed and approved by the medical monitor
•Aspartate transaminase / serum glutamic oxaloacetic transaminase (AST / SGOT) and alanine transaminase / serum glutamic pyruvic transaminase (ALT / SGPT) ≤3.0 x ULN;
•Must have, or be willing to have, an acceptable central catheter. (Port a cath, peripherally inserted central catheter [PICC] line, or central venous catheter).
•*FCBP is any sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (not having menstrual cycles due to cancer therapy does not rule out childbearing potential) for at least 24 consecutive months.

排除标准

•Primary refractory disease (i.e., never responded with ≥ minimal response [MR] to any prior therapy);
•Evidence of mucosal or internal bleeding and/or platelet transfusion refractory (platelet count fails to increase by >10,000 cells/mm³ [10.0 x 10⁹/L] after a transfusion of an appropriate dose of platelets);
•Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. Examples of such conditions are: a significant history of cardiovascular disease (e.g., myocardial infarction, significant conduction system abnormalities, uncontrolled hypertension, ≥Grade 3 thromboembolic event in the last 6 months);
•Known active infection requiring parenteral or oral anti-infective treatment within 14 days of initiation of therapy;
•Other malignancy diagnosed or requiring treatment within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in active surveillance;
•Pregnant or breast-feeding females;
•Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse compliance or follow-up evaluation;
•Known human immunodeficiency virus or active hepatitis B or C viral infection;
•Concurrent symptomatic amyloidosis or plasma cell leukemia;
•POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes);
•Previous cytotoxic therapies, including cytotoxic investigational agents, for MM within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within 30 days before initiation of therapy. Immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs) or corticosteroids within 2 weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within 4 weeks of initiation of therapy. Prednisone up to but no more than 10 mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to initiation of therapy;
•Residual side effects to previous therapy >Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 2 without pain are permitted);
•Prior peripheral stem cell transplant within 12 weeks of initiation of therapy;
•Prior allogeneic stem cell transplantation with active graft-versus-host-disease;
•Prior major surgical procedure or radiation therapy within 4 weeks of initiation of study therapy (this does not include limited course of radiation used for management of bone pain to be completed within 7 days of initiation of study therapy). Plasmapheresis is not permitted within 14 days of initiation of therapy;
•Known intolerance to steroid therapy;
•Prior renal transplant;
•Currently in need of renal dialysis.

研究组 & 干预措施

Cohort 1a

Experimental

Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg

干预措施: Melflufen (Drug)

Cohort 1a

Experimental

Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg

干预措施: Dexamethasone (Drug)

Cohort 1b

Experimental

Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg

干预措施: Melflufen (Drug)

Cohort 1b

Experimental

Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg

干预措施: Dexamethasone (Drug)

Cohort 2a

Experimental

Patients with severe renal impairment (eGFR ≥15 to <30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg

干预措施: Melflufen (Drug)

Cohort 2a

Experimental

Patients with severe renal impairment (eGFR ≥15 to <30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg

干预措施: Dexamethasone (Drug)